Amgen stock toppled Friday as investors digested its "generally in-line" first-quarter report and expansion in the obesity treatment space.

AMGN beats Q1 estimates as 16 drugs post double-digit growth, offsetting biosimilar erosion and weaker legacy products while lifting 2026 outlook.

Unfavorable lipid profiles are becoming a larger concern in primary care. A noted increase in dyslipidemia among children and ...

Amgen has launched a late-stage program to test the feasibility of switching patients from weekly GLP-1 injections to its own ...

Moby Strategic Performance and Portfolio Evolution. Management characterizes 2026 as a 'springboard year' where rapid growth ...

Amgen CEO Robert Bradway has declared 2026 a “springboard year” for the California big biotech, in which the growth of its ...

Good afternoon, everyone, and welcome to our first quarter of 2026 earnings call. Bob Bradway will lead the call today and be followed by a broader review of our performance by Murdo Gordon, Jay ...

Amgen on Thursday reported first-quarter product sales rose 4%, helped by demand for cholesterol and rare disease medicines, ...

The biotechnology company posted adjusted earnings per share of $5.15, beating the analyst consensus of $4.80 by $0.35. Revenue reached $8.62 billion, slightly above the $8.59 billion estimate and up ...

Amgen heads into Q1 earnings with growth from key drugs offset by pricing pressure, patent losses, and biosimilar competition.

Delve into the pipeline strategy of major biotech Amgen, which is increasingly diversifying its growth engines.